Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL04
- Pharmacological subgroupL04A
- Chemical subgroupL04AE
- Chemical substanceL04AE02Ozanimod
Where it is registered
Each register and historical list with its number of registrations and a few of them.
Netherlands
CBG-MEB · 3 registrations
Canada
Health Canada · 2 registrations
Spain
AEMPS · 2 registrations
At a glance
- ATC code
- L04AE02
- Registers
- 6
- Registrations
- 11
- With their own page
- 10
- Companies
- 5
All medicines with Ozanimod
Human medicines from every register that match Ozanimod by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
11 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Zeposia | United States | 0.23MG BASE, 0.46MG BASE, 0.92MG BASE | capsule | Marketed | Bristol |
| Zeposia | European Union | Authorised | Bristol-Myers Squibb Pharma EEIG | ||
| Zeposia 0,23 MG/0,46 MG Capsulas Duras | Spain | 0.25 mg + 0,5 mg | cápsula dura | Marketed | Bristol-Myers Squibb Pharma Eeig |
| Zeposia 0,92 MG Capsulas Duras | Spain | 1 mg | cápsula dura | Marketed | Bristol-Myers Squibb Pharma Eeig |
| Zeposia 0,23 mg capsule, hard | Netherlands | Capsule, hard | Authorised | Bristol-Myers Squibb Pharma EEIG | |
| Zeposia 0,46 mg capsule, hard | Netherlands | Capsule, hard | Authorised | Bristol-Myers Squibb Pharma EEIG | |
| Zeposia 0,92 mg capsule, hard | Netherlands | Capsule, hard | Authorised | Bristol-Myers Squibb Pharma EEIG | |
| Zeposia | Canada | 0.46 MG + 0.23 MG | Capsule | Marketed | Bristol-Myers Squibb Canada |
| Zeposia | Canada | 0.92 MG | Capsule | Marketed | Bristol-Myers Squibb Canada |
| Zeposia | Croatia | Authorised | |||
| Ozanimod | United States | 0.23MG, 0.46MG | capsule | Tentative approval | Synthon BV |